drugset / Trial / NCT04426474
A Study of LY3502970 in Participants With Type 2 Diabetes
RandomizedSequentialDouble-blindBasic science
Summary
The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.
Timeline
- Start
- 2020-10-08
- Primary completion
- 2021-07-12
- Completion
- 2021-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orforglipron | Small molecule | 3 mg | Oral |
| Subject | Orforglipron | Small molecule | 6 mg | Oral |
| Subject | Orforglipron | Small molecule | 9 mg | Oral |
| Subject | Orforglipron | Small molecule | 12 mg | Oral |
| Subject | Orforglipron | Small molecule | 15 mg | Oral |
| Subject | Orforglipron | Small molecule | 21 mg | Oral |
| Subject | Orforglipron | Small molecule | 27 mg | Oral |
| Subject | Orforglipron | Small molecule | 36 mg | Oral |
| Subject | Orforglipron | Small molecule | 45 mg | Oral |